Impact of Bone-targeted Therapies in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer Patients Treated with Abiraterone Acetate: Post Hoc Analysis of Study COU-AA-302

BACKGROUND: Metastatic castration-resistant prostate cancer (mCRPC) often involves bone, and bone-targeted therapy (BTT) has become part of the overall treatment strategy. OBJECTIVE: Investigation of outcomes for concomitant BTT in a post hoc analysis of the COU-AA-302 trial, which demonstrated an o...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Eur Urol
Autori principali: Saad, Fred, Shore, Neal, Van Poppel, Hendrik, Rathkopf, Dana E., Smith, Matthew R., de Bono, Johann S., Logothetis, Christopher J., de Souza, Paul, Fizazi, Karim, Mulders, Peter F.A., Mainwaring, Paul, Hainsworth, John D., Beer, Tomasz M., North, Scott, Fradet, Yves, Griffin, Thomas A., De Porre, Peter, Londhe, Anil, Kheoh, Thian, Small, Eric J., Scher, Howard I., Molina, Arturo, Ryan, Charles J.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2015
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5056561/
https://ncbi.nlm.nih.gov/pubmed/25985882
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eururo.2015.04.032
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi